×
| Stock | Total Income | Net Profit | Net Sales | EPS | Market Cap (in Cr) | P/E |
|---|---|---|---|---|---|---|
| FABINO ENTERPRISES LIMITED | NA | NA | NA | NA | 5.46 | 91.0 |
| Triochem Products Ltd., | NA | NA | NA | NA | 0 | |
| Vijaya Diagnostic Centre Limit | 1822.68 | 383.89 | 1748.45 | 3.73 | 11,367 | 75.4 |
| ALIVUS LIFE SCIENCES LIMITED | 6108.31 | 1215.35 | 6018.46 | 9.88 | 11293 | 22.8 |
| Metropolis Healthcare Limited | 3264.12 | 355.82 | 3236.32 | 6.84 | 11152 | 73.3 |
Vijaya Diagnostic Centre Limited, with Security Code 543350, is a leading player in the Healthcare Service Provider industry, categorized under the Healthcare sector, offering Equity instruments.
| Metrics | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 118.3 | 118.7 | 136.1 | 129.1 | 141.1 | 142.4 | 168.6 | 156.3 | 159.9 | 174.8 |
| Expenses | 70.2 | 71.2 | 79.8 | 78.0 | 83.8 | 86.7 | 98.4 | 93.8 | 95.6 | 105.5 |
| Operating Profit | 48.1 | 47.5 | 56.4 | 51.1 | 57.3 | 55.7 | 70.2 | 62.5 | 64.2 | 69.4 |
| OPM % | 40.64% | 40% | 41.41% | 39.57% | 40.59% | 39.12% | 41.61% | 39.98% | 40.19% | 39.68% |
| Other Income | 4.5 | 5.9 | 6.9 | 3.2 | 3.4 | 3.8 | 4.8 | 5.0 | 4.7 | 7.4 |
| Interest | 5.8 | 5.9 | 5.8 | 6.0 | 5.9 | 6.0 | 6.1 | 6.3 | 6.6 | 6.9 |
| Depreciation | 11.3 | 12.4 | 13.7 | 14.4 | 14.9 | 15.2 | 15.4 | 16.9 | 17.1 | 18.3 |
| Profit before tax | 35.5 | 35.0 | 43.8 | 35.9 | 39.8 | 38.3 | 53.5 | 44.3 | 46.2 | 51.6 |
| Tax % | -24.3% | -25.8% | -25% | -25.4% | -23.3% | -24.7% | -26.2% | 24.4% | -26.4% | 25.6% |
| Net Profit | 26.9 | 26.0 | 32.8 | 25.2 | 30.5 | 28.9 | 39.5 | 33.5 | 33.1 | 38.4 |
| EPS in Rs | 2.63 | 2.54 | 3.2 | 2.46 | 2.97 | 2.81 | 3.84 | 3.26 | 0 | 3.73 |
| Metrics | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 113.1 | 121.0 | 121.1 | 138.9 | 132.7 | 155.2 | 156.2 | 182.9 | 169.0 | 173.2 |
| Expenses | 68.8 | 71.9 | 72.9 | 81.5 | 80.4 | 92.1 | 95.0 | 107.0 | 101.9 | 104.3 |
| Operating Profit | 44.3 | 49.1 | 48.1 | 57.4 | 52.3 | 63.1 | 61.2 | 76.0 | 67.1 | 69.0 |
| OPM % | 39.15% | 40.59% | 39.75% | 41.31% | 39.42% | 40.66% | 39.2% | 41.53% | 39.73% | 39.8% |
| Other Income | 3.6 | 4.5 | 5.7 | 6.8 | 3.1 | 3.3 | 3.6 | 4.5 | 4.7 | 4.5 |
| Interest | 5.5 | 5.8 | 5.9 | 5.9 | 6.1 | 6.2 | 6.3 | 6.5 | 6.8 | 7.2 |
| Depreciation | 20.3 | 11.4 | 12.5 | 13.7 | 14.5 | 16.3 | 16.6 | 16.8 | 18.3 | 18.8 |
| Profit before tax | 22.0 | 36.5 | 35.5 | 44.6 | 36.8 | 43.9 | 41.9 | 57.2 | 46.7 | 48.5 |
| Tax % | -25.3% | -24% | -25.6% | -24.7% | -25.2% | -23.2% | 24.8% | 26.3% | -24.4% | -26.4% |
| Net Profit | 16.5 | 27.7 | 26.4 | 33.6 | 26.0 | 33.7 | 31.5 | 42.1 | 35.3 | 34.9 |
| EPS in Rs | 1.6 | 2.68 | 2.56 | 3.25 | 2.52 | 3.26 | 3.05 | 4.08 | 3.42 | 0 |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 14% |
| 3 Years: | 12% |
| TTM: | 19% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 19% |
| 3 Years: | 8% |
| TTM: | 32% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 0% |
| 3 Years: | 34% |
| 1 Year: | 20% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 15% |
| 3 Years: | 14% |
| TTM: | 24% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 20% |
| 3 Years: | 10% |
| TTM: | 34% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 0% |
| 3 Years: | 34% |
| 1 Year: | 20% |
Recent Bets
|
Date
|
Stock
|
Party
|
Deal
|
Acq. Mode
|
Trans.
|
Quan.
|
Price
|
Value
|
|---|
| Period | SMA Value | Status |
|---|
| Period | EMA Value | Status |
|---|
| Indicator | Value |
|---|